drugset
Drugs / BI 730357
last change Jan 2025 re-read 2 minutes ago

BI 730357

targets RORC via inhibition

Developed for
psoriasis · psoriatic arthritis
Investigated by
Boehringer Ingelheim

Trials 13 · a red edge is where a trial was stopped

today NCT04680676 · Ph 2 NCT04679948 · Ph 1 NCT04590937 · Ph 1 NCT04147260 · Ph 1 NCT03886272 · Ph 1 NCT03835481 · Ph 2 NCT03804671 · Ph 1 NCT03793621 · Ph 1 NCT03782987 · Ph 1 NCT03635099 · Ph 2 NCT03664011 · Ph 1 NCT03279978 · Ph 1 NCT03004404 · Ph 1
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials
Phase 1 NCT04679948 Dec 2020 → Mar 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04590937 Oct 2020 → Jan 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04147260 Nov 2019 → Sep 2020 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03886272 Apr → Jun 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03804671 Jan → Mar 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03793621 Jan → Apr 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03782987 Jan → Mar 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03664011 Sep → Nov 2018 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03279978 Jan → Aug 2018 psoriasis Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03004404 Jan → Aug 2017 — Boehringer Ingelheim Completed No outcome recorded
Phase 23 trials
Phase 2 NCT04680676 May 2022 → Jun 2023 psoriatic arthritis Boehringer Ingelheim Withdrawn No outcome recorded
Phase 2 NCT03835481 Mar 2019 → Jun 2021 psoriasis Boehringer Ingelheim Terminated No outcome recorded
Phase 2 NCT03635099 Sep 2018 → May 2021 psoriasis Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as BI 730357 “This 2-part, double-blinded trial assessed the RORγt inhibitor BI 730357 in plaque psoriasis.” PMID 39848568 ↗ Jan 2025
12

NCT04680676 ↗

NCT03664011 ↗

NCT03279978 ↗

NCT03782987 ↗

NCT03835481 ↗

NCT04590937 ↗

NCT03886272 ↗

NCT04679948 ↗

NCT04147260 ↗

NCT03793621 ↗

NCT03004404 ↗

NCT03804671 ↗
Action Inhibit “RORγt inhibitor BI 730357” PMID 39848568 ↗ Jan 2025
Route Oral “single oral dose of 2 milligram (mg) of BI 730357” NCT03004404 ↗
Target RORC “RORγt inhibitor BI 730357” PMID 39848568 ↗ Jan 2025